MedTrace Logo

Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device

NCT03803930 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1224

Last updated 2019-01-17

No results posted yet for this study

Summary

The purpose of this study is to compare the diagnosis accuracy of 22G EUS Procore fine needle biopsy （FNB）device and 20G EUS Procore fine needle biopsy device for solid pancreatic lesions.

Conditions

  • Pancreas Neoplasms

Interventions

DEVICE

Using 22G FNB, the first pass is SP

Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.

DEVICE

Using 22G FNB, the first pass is MWST

Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.

DEVICE

Using 20G FNB, the first pass is SP

Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.

DEVICE

Using 20G FNB, the first pass is MWST

Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Bin Cheng · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-06-01
Completion
2020-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03803930 on ClinicalTrials.gov